The U.S. FDA rejected Regeneron Pharmaceuticals’ attempt to secure a supplemental approval for the Tarrytown, N.Y.-based company’s blockbuster drug Eylea as a once-per 12-week treatment for wet age-related macular degeneration.

Following a disappointing 2017 that included an agreement to pay $40 million to resolve criminal charges against its subsidiary Aegerion, Canada-based Novelion Therapeutics will slash an unknown number of jobs as it initiates “significant cost reduction plans.”

Spark Therapeutics licensed rights to its breakthrough gene therapy Luxturna outside the United States to Switzerland-based Novartis.

Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.

Spark Therapeutics announced the price tag for its first-of-its-kind gene therapy for eye disease — $850,000 for both eyes.

People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.

Orchard Therapeutics said it raised $110 million in the second round of funding as the drug developer looks to launch its gene therapy to treat a rare inherited disorder and beef up manufacturing facilities.

The FDA approved Spark Therapeutics’ treatment for a rare form of blindness, marking the first time the U.S. regulatory agency approved a gene therapy for an inherited disease.

The FDA approved Aerie Pharmaceuticals Inc.’s eyedrop Rhopressa as a treatment for glaucoma, two months ahead of the expected date.

Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.